PKI - PerkinElmer to acquire U.K.-based in-vitro diagnostics company for $155M

PerkinElmer (PKI) and Immunodiagnostic Systems Holdings ((IDS)) have reached an agreement on the terms of a recommended all cash offer whereby PerkinElmer will acquire IDS for ~$155M (£110M).The transaction has a total enterprise value of ~$124M (£88M) and is expected to close early in Q3 2021. Through this acquisition, PerkinElmer will be able to grow its overall Diagnostics business and specifically its immunodiagnostics segment. Moreover, the deal will enable PerkinElmer to combine its channel expertise and testing capabilities with IDS’s chemiluminescence products in endocrinology, autoimmunity and infectious diseases. IDS’s portfolio and expertise will seamlessly integrate within EUROIMMUN, a PerkinElmer company since 2017. Headquartered in Boldon, the U.K., IDS is an in-vitro diagnostic solution provider to the clinical laboratory market. IDS develops, manufactures, and markets innovative immunoassays and automated immunoanalyzer technologies to provide improved diagnostic outcomes for patients.

For further details see:

PerkinElmer to acquire U.K.-based in-vitro diagnostics company for $155M